Kevin McCulloch's most recent trade in Xeris Biopharma Holdings Inc was a trade of 90,000 Common Stock done at an average price of $8.0 . Disclosure was reported to the exchange on July 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Sale of securities on an exchange or to another person at price $ 8.03 per share. | 01 Jul 2026 | 90,000 | 1,691,126 (6%) | 0% | 8.0 | 722,511 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 12 Mar 2026 | 48,894 | 1,777,721 (6%) | 0% | 4.1 | 199,976 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 48,894 | 43,773 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.00 per share. | 12 Mar 2026 | 4 | 1,777,725 (6%) | 0% | 4 | 16 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 4 | 79,996 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 225,225 | 225,225 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 168,463 | 1,853,889 (6%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.36 per share. | 30 Jan 2026 | 68,454 | 1,785,435 (6%) | 0% | 7.4 | 503,821 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.36 per share. | 30 Jan 2026 | 30,289 | 1,755,146 (6%) | 0% | 7.4 | 222,927 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.36 per share. | 30 Jan 2026 | 27,319 | 1,727,827 (6%) | 0% | 7.4 | 201,068 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 08 Jan 2026 | 15,000 | 1,685,426 (6%) | 0% | 8 | 120,000 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.31 per share. | 02 Oct 2025 | 733 | 1,700,426 (6%) | 0% | 8.3 | 6,091 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Other type of transaction at price $ 0.00 per share. | 11 Sep 2025 | 2,000 | 0 (0%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.38 per share. | 01 Aug 2025 | 14,651 | 1,701,159 (6%) | 0% | 5.4 | 78,822 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Purchase of securities on an exchange or from another person at price $ 4.38 per share. | 13 Jun 2025 | 25,000 | 1,708,585 (6%) | 0% | 4.4 | 109,475 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.15 per share. | 02 Apr 2025 | 733 | 1,683,585 (6%) | 0% | 5.2 | 3,775 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 500,000 | 500,000 | - | - | Stock Appreciation Right | |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 185,000 | 1,684,318 (6%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 31 Jan 2025 | 48,834 | 1,499,318 (5%) | 0% | 3.6 | 173,849 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 31 Jan 2025 | 29,300 | 1,548,152 (5%) | 0% | 3.6 | 104,308 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.61 per share. | 03 Jan 2025 | 24,501 | 1,577,452 (5%) | 0% | 3.6 | 88,449 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 200,000 | 200,000 | - | - | Stock Appreciation Right | |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 150,000 | 1,601,953 (5%) | 0% | 0 | Common Stock |